Matthew Plavan
2007 - Cesca Therapeutics
In 2007, Matthew Plavan earned a total compensation of $280.6K as Chief Financial Officer at Cesca Therapeutics.
Compensation breakdown
| Option Awards | $56,602 |
|---|---|
| Salary | $199,981 |
| Stock Awards | $19,833 |
| Other | $4,219 |
| Total | $280,635 |
Plavan received $200K in salary, accounting for 71% of the total pay in 2007.
Plavan also received $56.6K in option awards, $19.8K in stock awards and $4.2K in other compensation.
Rankings
In 2007, Matthew Plavan's compensation ranked 7,563rd out of 8,700 executives tracked by ExecPay. In other words, Plavan earned more than 13.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,563 out of 8,700 | 13th |
Division Manufacturing | 2,909 out of 3,314 | 12th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 443 out of 527 | 16th |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 161 out of 203 | 21st |
Industry Laboratory Apparatus and Furniture | 3 out of 6 | 50th |
Source: SEC filing on October 26, 2007.
Plavan's colleagues
We found five more compensation records of executives who worked with Matthew Plavan at Cesca Therapeutics in 2007.
2007
Philip Coelho
Cesca Therapeutics
Chief Executive Officer
2007
Kevin Simpson
Cesca Therapeutics
Former President and GM, Surgical Wound Care
2007
John Chapman
Cesca Therapeutics
V.P. of Scientific Affairs
2007
Dennis Marr
Cesca Therapeutics
V.P. Research and Development
2007
William Osgood
Cesca Therapeutics
Chief Operating Officer
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019